Frank Sams-Dodd

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. ncbi request reprint (+) MK-801 and phencyclidine induced neurotoxicity do not cause enduring behaviours resembling the positive and negative symptoms of schizophrenia in the rat
    Frank Sams-Dodd
    Pharmacological Research, H Lundbeck A S, Ottiliavej 9, DK 2500 Valby, Denmark
    Basic Clin Pharmacol Toxicol 95:241-6. 2004
  2. ncbi request reprint Target-based drug discovery: is something wrong?
    Frank Sams-Dodd
    Boehringer Ingelheim Pharma, GmbH and Co KG, D 88397, Biberach, Germany
    Drug Discov Today 10:139-47. 2005
  3. ncbi request reprint Optimizing the discovery organization for innovation
    Frank Sams-Dodd
    Boehringer Ingelheim Pharma GmbH, D 88397 Biberach a d Riss, Germany
    Drug Discov Today 10:1049-56. 2005
  4. ncbi request reprint The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats
    Eliza Koros
    Department of CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Neuropsychopharmacology 32:562-76. 2007
  5. ncbi request reprint Drug discovery: selecting the optimal approach
    Frank Sams-Dodd
    Bionomics Europe, Les Algorithmes, rue Jean Sapidus, Parc d Innovation, 67400 Illkirch, France
    Drug Discov Today 11:465-72. 2006
  6. ncbi request reprint Strategies to optimize the validity of disease models in the drug discovery process
    Frank Sams-Dodd
    Bionomics Europe, Les Algorithmes, rue Jean Sapidus, Parc d Innovation, 67400 Illkirch, France
    Drug Discov Today 11:355-63. 2006
  7. ncbi request reprint Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine
    Marianne H Larsen
    Department of Translational Neurobiology, Neurosearch A S, Pederstrupvej 93, 2750 Ballerup, Denmark
    Eur J Pharmacol 555:115-21. 2007
  8. ncbi request reprint Research & market strategy: how choice of drug discovery approach can affect market position
    Frank Sams-Dodd
    Bionomics Ltd Europe, rue Jean Sapidus, Parc d Innovation, F 67400 Illkirch, France
    Drug Discov Today 12:314-8. 2007

Detail Information

Publications8

  1. ncbi request reprint (+) MK-801 and phencyclidine induced neurotoxicity do not cause enduring behaviours resembling the positive and negative symptoms of schizophrenia in the rat
    Frank Sams-Dodd
    Pharmacological Research, H Lundbeck A S, Ottiliavej 9, DK 2500 Valby, Denmark
    Basic Clin Pharmacol Toxicol 95:241-6. 2004
    ..The rats did not show any enduring behavioural changes as a result of the treatment. The present study could therefore not provide additional evidence for the face validity of this model of schizophrenia...
  2. ncbi request reprint Target-based drug discovery: is something wrong?
    Frank Sams-Dodd
    Boehringer Ingelheim Pharma, GmbH and Co KG, D 88397, Biberach, Germany
    Drug Discov Today 10:139-47. 2005
    ....
  3. ncbi request reprint Optimizing the discovery organization for innovation
    Frank Sams-Dodd
    Boehringer Ingelheim Pharma GmbH, D 88397 Biberach a d Riss, Germany
    Drug Discov Today 10:1049-56. 2005
    ....
  4. ncbi request reprint The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats
    Eliza Koros
    Department of CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    Neuropsychopharmacology 32:562-76. 2007
    ..These data demonstrate that social behavior deficits in rats can be caused by both the blockade of the NMDA receptor and the inhibition of mGluR5, whereas mGluR5 antagonists may not independently be able to mimic the positive symptoms...
  5. ncbi request reprint Drug discovery: selecting the optimal approach
    Frank Sams-Dodd
    Bionomics Europe, Les Algorithmes, rue Jean Sapidus, Parc d Innovation, 67400 Illkirch, France
    Drug Discov Today 11:465-72. 2006
    ..This paper evaluates the strengths and limitations of the main drug discovery approaches, and proposes a novel approach that could offer advantages for the identification of disease-modifying treatments...
  6. ncbi request reprint Strategies to optimize the validity of disease models in the drug discovery process
    Frank Sams-Dodd
    Bionomics Europe, Les Algorithmes, rue Jean Sapidus, Parc d Innovation, 67400 Illkirch, France
    Drug Discov Today 11:355-63. 2006
    ..The purpose of this paper is, therefore, to provide a theoretical discussion of the concepts behind disease models and to develop a terminology and a framework to analyze and express the clinical validity of disease models...
  7. ncbi request reprint Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine
    Marianne H Larsen
    Department of Translational Neurobiology, Neurosearch A S, Pederstrupvej 93, 2750 Ballerup, Denmark
    Eur J Pharmacol 555:115-21. 2007
    ..This study shows that Tesofensine enhances hippocampal gene expression and new cell formation indicative for an antidepressant potential of this novel drug substance...
  8. ncbi request reprint Research & market strategy: how choice of drug discovery approach can affect market position
    Frank Sams-Dodd
    Bionomics Ltd Europe, rue Jean Sapidus, Parc d Innovation, F 67400 Illkirch, France
    Drug Discov Today 12:314-8. 2007
    ..However, a comparison of approaches from the perspective of market position indicates that the functional approach is superior for the development of novel, innovative treatments...